Novartis Vaccines & Diagnostics, Inc.
US Flu Cell Culture Facility
Novartis Vaccines and Diagnostics, a subsidiary of Novartis AG of Basel, Switzerland, will bring approximately 350 new jobs for the new vaccine manufacturing facility in Holly Springs, North Carolina. The 500,000 square foot structure will be the first manufacturing plant in the U.S. to produce cell culture-derived flu vaccines using new technologies. The facility is being constructed on a 167-acre site in the Holly Springs Business Park. Blair Concrete’s scope of work includes Excavation, Foundations, Auger Cast Piles and Building Ground Grid System. Once completed and approved for commercial production the facility is expected to annually produce up to 50 million doses of seasonal trivalent flu vaccines, which will be for use in the U.S.
PROJECT SPECIFICS:
Holly Springs, North Carolina
500,000 SF
6000 CY
Peak Crew Size: 50
